Incyte, Novartis: Positive CHMP Opinion for Jakavi for Graft-Versus-Host Disease

 

• he positive opinion from the CHMP is based on data from the Phase 3 REACH2 and REACH3 trials, which demonstrated that ruxolitinib (Jakavi®) improved response rates and failure-free survival compared to best available therapy, which provides a promising opportunity for patients living with graft-versus-host disease (GvHD)1,2

• Graft-versus-host disease (GVHD) is a life-threatening complication of stem cell transplants, with no established standard of care in Europe for patients who do not adequately respond to first-line steroid treatment3,4

• Nearly half of patients experience acute or chronic GVHD following allogeneic transplants 3,4

https://finance.yahoo.com/news/incyte-announces-positive-chmp-opinion-123000135.html